G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022

On January 4, 2022 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that the Company will participate in two upcoming virtual investor conferences in January (Press release, G1 Therapeutics, JAN 4, 2022, View Source [SID1234598069]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

G1’s Chief Executive Officer Jack Bailey and Chief Medical Officer Raj Malik, M.D. will participate in a fireside chat during the H.C. Wainwright BioConnect 2022 conference. The webcast of the fireside chat will become available at 7:00 AM EST on January 10, 2022.
On January 12, 2022, at 1:30 PM EST, Mr. Bailey will provide a corporate presentation during the 40th Annual J.P. Morgan Healthcare Conference.
The webcast of both events will be accessible on the Events & Presentations page of View Source